285 related articles for article (PubMed ID: 27310202)
1. Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946).
Scott WJ; Hentemann MF; Rowley RB; Bull CO; Jenkins S; Bullion AM; Johnson J; Redman A; Robbins AH; Esler W; Fracasso RP; Garrison T; Hamilton M; Michels M; Wood JE; Wilkie DP; Xiao H; Levy J; Stasik E; Liu N; Schaefer M; Brands M; Lefranc J
ChemMedChem; 2016 Jul; 11(14):1517-30. PubMed ID: 27310202
[TBL] [Abstract][Full Text] [Related]
2. Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib.
Krause G; Hassenrück F; Hallek M
Drug Des Devel Ther; 2018; 12():2577-2590. PubMed ID: 30174412
[TBL] [Abstract][Full Text] [Related]
3. BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models.
Liu N; Rowley BR; Bull CO; Schneider C; Haegebarth A; Schatz CA; Fracasso PR; Wilkie DP; Hentemann M; Wilhelm SM; Scott WJ; Mumberg D; Ziegelbauer K
Mol Cancer Ther; 2013 Nov; 12(11):2319-30. PubMed ID: 24170767
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel quinazoline derivatives as potent PI3Kδ inhibitors with high selectivity.
Teng Y; Li X; Ren S; Cheng Y; Xi K; Shen H; Ma W; Luo G; Xiang H
Eur J Med Chem; 2020 Dec; 208():112865. PubMed ID: 32987316
[TBL] [Abstract][Full Text] [Related]
5. Introduction of pyrrolidineoxy or piperidineamino group at the 4-position of quinazoline leading to novel quinazoline-based phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
Xin M; Duan W; Feng Y; Hei YY; Zhang H; Shen Y; Zhao HY; Mao S; Zhang SQ
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):651-656. PubMed ID: 29536777
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3Kα.
Ding HW; Deng CL; Li DD; Liu DD; Chai SM; Wang W; Zhang Y; Chen K; Li X; Wang J; Song SJ; Song HR
Eur J Med Chem; 2018 Feb; 146():460-470. PubMed ID: 29407971
[TBL] [Abstract][Full Text] [Related]
7. Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors.
Liu KK; Huang X; Bagrodia S; Chen JH; Greasley S; Cheng H; Sun S; Knighton D; Rodgers C; Rafidi K; Zou A; Xiao J; Yan S
Bioorg Med Chem Lett; 2011 Feb; 21(4):1270-4. PubMed ID: 21269826
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of quinazolines as tyrosine kinase inhibitors.
Srivastava SK; Kumar V; Agarwal SK; Mukherjee R; Burman AC
Anticancer Agents Med Chem; 2009 Mar; 9(3):246-75. PubMed ID: 19275520
[TBL] [Abstract][Full Text] [Related]
9. Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation.
Okabe S; Tanaka Y; Tauchi T; Ohyashiki K
Ann Hematol; 2019 Mar; 98(3):723-733. PubMed ID: 30430191
[TBL] [Abstract][Full Text] [Related]
10. Identification and structure-activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors.
Pecchi S; Renhowe PA; Taylor C; Kaufman S; Merritt H; Wiesmann M; Shoemaker KR; Knapp MS; Ornelas E; Hendrickson TF; Fantl W; Voliva CF
Bioorg Med Chem Lett; 2010 Dec; 20(23):6895-8. PubMed ID: 21035331
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
Hou J; Wan S; Wang G; Zhang T; Li Z; Tian Y; Yu Y; Wu X; Zhang J
Eur J Med Chem; 2016 Aug; 118():276-89. PubMed ID: 27132165
[TBL] [Abstract][Full Text] [Related]
12. Novel 6-aryl substituted 4-pyrrolidineaminoquinazoline derivatives as potent phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
Xin M; Duan W; Feng Y; Hei YY; Zhang H; Shen Y; Zhao HY; Mao S; Zhang SQ
Bioorg Med Chem; 2018 May; 26(8):2028-2040. PubMed ID: 29534936
[TBL] [Abstract][Full Text] [Related]
13. Copanlisib: Novel PI3K Inhibitor for the Treatment of Lymphoma.
Kumar A; Bhatia R; Chawla P; Anghore D; Saini V; Rawal RK
Anticancer Agents Med Chem; 2020; 20(10):1158-1172. PubMed ID: 32183683
[TBL] [Abstract][Full Text] [Related]
14. Novel 4-aminoquinazoline derivatives induce growth inhibition, cell cycle arrest and apoptosis via PI3Kα inhibition.
Fan YH; Ding HW; Liu DD; Song HR; Xu YN; Wang J
Bioorg Med Chem; 2018 May; 26(8):1675-1685. PubMed ID: 29475582
[TBL] [Abstract][Full Text] [Related]
15. The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326).
Heffron TP; Heald RA; Ndubaku C; Wei B; Augistin M; Do S; Edgar K; Eigenbrot C; Friedman L; Gancia E; Jackson PS; Jones G; Kolesnikov A; Lee LB; Lesnick JD; Lewis C; McLean N; Mörtl M; Nonomiya J; Pang J; Price S; Prior WW; Salphati L; Sideris S; Staben ST; Steinbacher S; Tsui V; Wallin J; Sampath D; Olivero AG
J Med Chem; 2016 Feb; 59(3):985-1002. PubMed ID: 26741947
[TBL] [Abstract][Full Text] [Related]
16. Rational design of phosphoinositide 3-kinase α inhibitors that exhibit selectivity over the phosphoinositide 3-kinase β isoform.
Heffron TP; Wei B; Olivero A; Staben ST; Tsui V; Do S; Dotson J; Folkes AJ; Goldsmith P; Goldsmith R; Gunzner J; Lesnick J; Lewis C; Mathieu S; Nonomiya J; Shuttleworth S; Sutherlin DP; Wan NC; Wang S; Wiesmann C; Zhu BY
J Med Chem; 2011 Nov; 54(22):7815-33. PubMed ID: 21985639
[TBL] [Abstract][Full Text] [Related]
17. Biophysical and Structural Characterization of Novel RAS-Binding Domains (RBDs) of PI3Kα and PI3Kγ.
Martinez NG; Thieker DF; Carey LM; Rasquinha JA; Kistler SK; Kuhlman BA; Campbell SL
J Mol Biol; 2021 Apr; 433(8):166838. PubMed ID: 33539876
[TBL] [Abstract][Full Text] [Related]
18. 2,4-Disubstituted quinazolines targeting breast cancer cells via EGFR-PI3K.
Li ED; Lin Q; Meng YQ; Zhang LY; Song PP; Li N; Xin JC; Yang P; Bao CN; Zhang DQ; Zhang Y; Wang JK; Zhang QR; Liu HM
Eur J Med Chem; 2019 Jun; 172():36-47. PubMed ID: 30939352
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino-N-(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents.
Peng W; Tu ZC; Long ZJ; Liu Q; Lu G
Eur J Med Chem; 2016 Jan; 108():644-654. PubMed ID: 26731167
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, initial SAR and biological evaluation of 1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-amine derived inhibitors of IkappaB kinase.
Kempson J; Guo J; Das J; Moquin RV; Spergel SH; Watterson SH; Langevine CM; Dyckman AJ; Pattoli M; Burke JR; Yang X; Gillooly KM; McIntyre KW; Chen L; Dodd JH; McKinnon M; Barrish JC; Pitts WJ
Bioorg Med Chem Lett; 2009 May; 19(10):2646-9. PubMed ID: 19376699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
